Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2013

01-12-2013 | Research Article

Regulation of BMI1 Polycomb gene expression in histological grades of invasive ductal breast carcinomas and its correlation with hormone receptor status

Authors: M. V. S. Parvathi, P. Balakrishna Murthy, M. Vennila, B. V. Suresh

Published in: Tumor Biology | Issue 6/2013

Login to get access

Abstract

BMI1 is the first functional mammalian Polycomb group (PcG) proto-oncogene involved in multiple biological processes. Regulation of B cell-specific Moloney murine leukaemia virus integration site 1 (BMI1) expression with increase in histological grades of breast carcinoma in correlation with hormone receptor status was studied in 60 Indian breast cancer patient's formalin-fixed paraffin-embedded tissue blocks. Relative expression of BMI1 was studied using real-time PCR. Immunohistochemistry explained the distribution of hormone receptor markers. Correlation of BMI1 gene expression with oestrogen receptor, progesterone receptor (PR) and human epidermal growth factor receptor 2/neu status was analysed using Hex—protein docking tool. The hormone receptor expression was reduced with increasing grades of breast tumour. BMI1 gene expression was downregulated (real-time polymerase chain reaction analysis). Docking analysis explained the correlation between BMI1 and PR expression. BMI1 gene was co-regulated (down) with PR in the invasive ductal breast carcinoma with relative progression explicating it a diagnostic biomarker for ductal carcinoma of the breast.
Literature
1.
Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. PNAS. 2003;100(10):5974–9.PubMedCrossRef
2.
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRef
3.
Gasparini G, Pozza F. Evaluating the potential usefulness of new prognostic and predictive indicators in node negative breast cancer patients. J Natl Cancer Inst. 1993;85:1206–19.PubMedCrossRef
4.
Haupt Y, Alexander WS, Barri G, et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Emu-myc transgenic mice. Cell. 1991;65:753–63.PubMedCrossRef
5.
Van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological, abnormalities, and severe hematopoitetic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8:757–69.PubMedCrossRef
6.
Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001;84:1372–6.PubMedCrossRef
7.
Zhang F, Sui L, Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. ExpOncol. 2008;30:70–4.
8.
Masashi S, Kazuhito Y, Toshiya Y, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol. 2005;82:42–7.CrossRef
9.
Li-Bing S, Mu-Sheng Z, Wen-Ting L, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006;66:6225–32.CrossRef
10.
Dimri GP, Martinez JL, Jacobs JJ, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002;62:4736–45.PubMed
11.
Hongjuan C, Bo H, Tai L, et al. Bmi-1 is essential for the tumourigenicity of neuroblastoma cells. Am J Pathol. 2007;170:1370–8.CrossRef
12.
Silva J, García V, García JM, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Research. 2007;9:R55.PubMedCrossRef
13.
Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene. 2006;25:4370–5.PubMedCrossRef
14.
Lee K, Adhikary G, Balasubramanian S, et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol. 2008;128:9–17.PubMedCrossRef
15.
Choi YJ, Choi YL, Cho EY, et al. Expression of Bmi-1 protein in tumour tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat. 2009;113:83–93.PubMedCrossRef
16.
17.
Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–56.PubMedCrossRef
18.
Van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRef
19.
Saeki M, Kobayashi D, Tsuji N, et al. Diagnostic importance of over expression of Bmi-1 mRNA in early breast cancers. Int J Onc. 2009;35:511–5.
20.
Engelsen IB, Mannelqvist M, Stefansson IM, et al. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer. 2008;98:1662–9.PubMedCrossRef
21.
Alexandra MP, Bastiaan E, Asheeta AP, et al. Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr Biol. 2008;18:1094–9.CrossRef
22.
Wei-J G, Mu-Sheng Z, Ajay Y, et al. Mel-18 acts as a tumour suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 2007;67(11):5083–9.CrossRef
Metadata
Title
Regulation of BMI1 Polycomb gene expression in histological grades of invasive ductal breast carcinomas and its correlation with hormone receptor status
Authors
M. V. S. Parvathi
P. Balakrishna Murthy
M. Vennila
B. V. Suresh
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0965-y

Other articles of this Issue 6/2013

Tumor Biology 6/2013 Go to the issue

Research Article

RETRACTED ARTICLE: MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1

Research Article

Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis

Research Article

A systematic review of p53 as a biomarker of survival in patients with osteosarcoma

Research Article

High expression of M3 muscarinic acetylcholine receptor is a novel biomarker of poor prognostic in patients with non-small cell lung cancer

Research Article

Prognostic value of cyclin E expression in breast cancer: a meta-analysis

Research Article

Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits